The anti-COPT1-IgM autoantibody could discriminate early NSCLC from NC, with an AUC of 0.683 (95% CI: 0.636-0.731, sensitivity=49.4%, specificity=77.9%) (Figure 7D, Supplementary Figure 4A). These results indicated the potential of anti-COPT1 autoantibodies as biomarkers for the detection of early NSCLC. The gene discussed is SLC31A1; the disease is non-small cell lung carcinoma.